Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Finished Drug Prices
NA
1. 3-formylamino-7-methylsulfonylamino-6-phenoxy-4h-1-benzopyran-4-one
2. T 614
3. T-614
1. 123663-49-0
2. N-(7-(methylsulfonamido)-4-oxo-6-phenoxy-4h-chromen-3-yl)formamide
3. Careram
4. Kolbet
5. T-614
6. Iguratimod [inn]
7. Iremod
8. 4ihy34y2nv
9. 3-formylamino-7-methylsulfonylamino-6-phenoxy-4h-1-benzopyran-4-one
10. Ncgc00181783-02
11. T614
12. N-[7-(methanesulfonamido)-4-oxo-6-phenoxychromen-3-yl]formamide
13. N-[7-methanesulfonamido-4-oxo-6-(phenoxy)chromen-3-yl]formamide
14. N-(7-((methylsulfonyl)amino)-4-oxo-6-phenoxy-4h-1-benzopyran-3-yl)formamide
15. Unii-4ihy34y2nv
16. Colvet
17. T 614
18. Iguratimod- Bio-x
19. Iguratimod [mi]
20. Iguratimod (jan/inn)
21. Iguratimod [jan]
22. Dsstox_cid_28897
23. Dsstox_rid_83165
24. Iguratimod [who-dd]
25. Dsstox_gsid_48971
26. Schembl26326
27. Gtpl9736
28. Chembl2107455
29. Dtxsid0048971
30. Iguratimod, >=98% (hplc)
31. Chebi:31689
32. Bcp04206
33. Tox21_113422
34. Bdbm50458537
35. Mfcd00882374
36. S5648
37. Akos015888743
38. Zinc100018451
39. Ccg-268349
40. Cs-0617
41. Db12233
42. Sb16814
43. Ncgc00181783-01
44. Ncgc00181783-03
45. As-12959
46. Bi164569
47. Hy-17009
48. A3484
49. Cas-123663-49-0
50. Ft-0654508
51. I0945
52. C71931
53. D01146
54. 663i490
55. A805134
56. Sr-01000945251
57. J-521483
58. Sr-01000945251-1
59. Q13575264
60. N-(3-formamido-4-oxo-6-phenoxy-4h-chromen-7-yl)methanesulfonamide
61. N-[7-(methanesulfonamido)-4-oxo-6-phenoxy-4h-chromen-3-yl]formamide
62. N-[7-(methanesulfonamido)-4-oxo-6-phenoxy-chromen-3-yl]formamide;iguratimod
Molecular Weight | 374.4 g/mol |
---|---|
Molecular Formula | C17H14N2O6S |
XLogP3 | 1.4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 5 |
Exact Mass | 374.05725734 g/mol |
Monoisotopic Mass | 374.05725734 g/mol |
Topological Polar Surface Area | 119 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 665 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
Registration Number : 305MF10057
Registrant's Address : No. 12 Zhangma Road, Salt and Chemical New Materials Industrial Park, Huai\'an Jiangsu Province, P. R. China
Initial Date of Registration : 2023-05-10
Latest Date of Registration : --
Registration Number : 302MF10127
Registrant's Address : No. 2, Yaogu 3rd Road, Pharma Valley, Xiuying District, Haikou City, Hainan Province, 570311, China
Initial Date of Registration : 2020-10-14
Latest Date of Registration : --
Registration Number : 302MF10085
Registrant's Address : No. 9 Hantai North Road, Qinghe District, Huai\'an City, Jiangsu Province, P. R. China
Initial Date of Registration : 2020-07-22
Latest Date of Registration : --
Registration Number : 305MF10057
Registrant's Address : No. 12 Zhangma Road, Salt and Chemical New Materials Industrial Park, Huai'an Jiangsu...
Initial Date of Registration : 2023-05-10
Latest Date of Registration : 2024-07-24
Registration Number : 302MF10085
Registrant's Address : No. 9 Hantai North Road, Qinghe District, Huai'an City, Jiangsu Province, P. R. China
Initial Date of Registration : 2020-07-22
Latest Date of Registration : 2023-08-02
Registration Number : 302MF10127
Registrant's Address : No. 2, Yaogu 3rd Road, Pharma Valley, Xiuying District, Haikou City, Hainan Province,...
Initial Date of Registration : 2020-10-14
Latest Date of Registration : 2020-10-14
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
About the Company : Established in 2004 and headquartered in Hangzhou, Hengkang established multiple factories, research and sales centers in Zhejiang, Shandong, and Henan. With facilities conforming ...
About the Company : Allastir instituted the services in 2010 with a motive to cater the pharmaceutical industry with niche API's. In Allastir we strongly believe in team work and customer satisfaction...
About the Company : Guangzhou Topwork Chemical Co., Ltd. Specializes in manufacturing corticosteroid and relative intermediates. We provide high quality products and excellent service to our clients a...
About the Company : Lewens Labs finds its roots in 4 years of engineering during which we saw a dream to carve out a niche for ourselves in Pharmaceutical Industry. As a part of the final year project...
About the Company : We are Maiden, a rapidly growing Indian pharma company committed to developing, manufacturing and marketing diverse portfolio of products. Our core strength lies in development, up...
About the Company : Medilux Laboratories has been providing quality back-end support to the pharmaceutical industry since our inception in 1988. Our resources are dedicated to promoting better health ...
About the Company : Established in 1999, Hankang Pharmaceutical Group stands as a prominent CRO-CDMO integrated service enterprise in China. Focused on generic drugs while venturing into innovative on...
About the Company : Yangtze River Pharmaceutical Group (hereinafter refers to YRPG) was founded in 1971, with over 9000 employees. Comprehensive competitiveness of YRPG has been ranked in the top five...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
N-(4-(2-aminoacetyl)-5-methoxy-2-phenoxyphenyl)met...
CAS Number : 149436-41-9
End Use API : Iguratimod
About The Company : Hiray Pharma Solutions is an international end-to-end CDMO, facilitating the development and manufacturing of important drug products and key intermediates arou...
13 May 2019
// BIOSPECTRUM ASIA
https://www.biospectrumasia.com/news/28/13440/vedanta-biosciences-closes-extended-45-5-million-series-c-funding.html
Global Sales Information
Market Place
ABOUT THIS PAGE
A Iguratimod manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Iguratimod, including repackagers and relabelers. The FDA regulates Iguratimod manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Iguratimod API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Iguratimod manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Iguratimod supplier is an individual or a company that provides Iguratimod active pharmaceutical ingredient (API) or Iguratimod finished formulations upon request. The Iguratimod suppliers may include Iguratimod API manufacturers, exporters, distributors and traders.
click here to find a list of Iguratimod suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Iguratimod Drug Master File in Japan (Iguratimod JDMF) empowers Iguratimod API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Iguratimod JDMF during the approval evaluation for pharmaceutical products. At the time of Iguratimod JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Iguratimod suppliers with JDMF on PharmaCompass.
Iguratimod Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Iguratimod GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Iguratimod GMP manufacturer or Iguratimod GMP API supplier for your needs.
A Iguratimod CoA (Certificate of Analysis) is a formal document that attests to Iguratimod's compliance with Iguratimod specifications and serves as a tool for batch-level quality control.
Iguratimod CoA mostly includes findings from lab analyses of a specific batch. For each Iguratimod CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Iguratimod may be tested according to a variety of international standards, such as European Pharmacopoeia (Iguratimod EP), Iguratimod JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Iguratimod USP).
LOOKING FOR A SUPPLIER?